GlassScriptPhysician profile
Colby Morton
NPI 1124569991
$106,561.02
in general payments reported to CMS, 2019-2025
41 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13K · 2022: $37K · 2023: $25K · 2024: $17K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Food and Beverage: $6,223 · Travel and Lodging: $291 · Education: $62.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $49,525.00 |
| Food and Beverage | $6,223.28 |
| Travel and Lodging | $290.93 |
| Education | $62.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $96,177.77 | 2021-2025 | Minimed 780g, Minimed 770g |
| Amgen INC. | $968.49 | 2024-2025 | Tepezza, Krystexxa, Uplizna |
| Lilly USA, LLC | $901.69 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $805.42 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $805.07 | 2021-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $759.03 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $731.66 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $587.14 | 2021-2025 | Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $517.17 | 2021-2024 | |
| Dexcom, INC. | $413.98 | 2021-2025 | Dexcom G6 Transmitter |
| Alexion Pharmaceuticals, INC. | $377.65 | 2023-2025 | Strensiq |
| Abbott Laboratories | $342.59 | 2021-2025 | Freestyle Libre 3, Proclaim, Eterna |
| Insulet Corporation | $303.85 | 2021-2025 | Omnipod |
| Mannkind Corporation | $280.56 | 2021-2025 | Afrezza |
| Ultragenyx Pharmaceutical INC. | $255.59 | 2021-2025 | Crysvita |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colby Morton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.